Aadi Bioscience, Inc.

  • Moat Score
  • Market Cap $51.69M
  • PE -1
  • Debt $NaN
  • Cash $30.54M
  • EV $NaN
  • FCF -$56.43M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$61.69M
EBIT-$64.78M
ROE-90%
ROA-76%
FCF-$56.43M
Equity$68.87M
Growth Stability1
PE-0.84
PB0.75
P/FCF-0.92
P/S2.06
Price/Cash0.59
Net Margins-242%
Gross Margins87%
Op. Margins-258%
Sales Growth YoY21%
Sales Growth QoQ17%
Sales CAGR6%
Equity CAGR25%
Earnings Growth YoY-23%
Earnings Growth QoQ-14%
Sales CAGR 5Y131%
Equity CAGR 5Y28%
Earnings CAGR 3Y20%
Sales CAGR 3Y20%
Equity CAGR 3Y-20%
Market Cap$51.69M
Revenue$25.07M
Dividend Yield0%
Payout Ratio-0%
Assets$85.70M
Cash$30.54M
Shares Outstanding24.61M
Moat Score1%
Working Capital61.5M
Current Ratio4.89
Shares Growth 3y7%
Equity Growth QoQ-13%
Equity Growth YoY-42%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.

SEC Filings

Direct access to Aadi Bioscience, Inc. (AADI) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Aadi Bioscience, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Aadi Bioscience, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Aadi Bioscience, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Aadi Bioscience, Inc..

= -$564M
012345678910TV
fcf-$56M-$56M-$56M-$56M-$56M-$56M-$56M-$56M-$56M-$56M-$56M-$564M
DCF-$51M-$47M-$42M-$39M-$35M-$32M-$29M-$26M-$24M-$22M-$218M
Value-$564M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-----52%--29%-791%-398%-270%-242%
ROA--124%-735%-102%-17%-61%-8%-70%-33%-50%-76%
ROE-17%9K%-128%-18%-64%-10%-81%-38%-63%-90%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-------1.87----
Debt over Equity---54.83---0.24----
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth------100%--7%9%60%131%
Earnings YoY growth--85%66K%7%-53%124%-81%2K%-45%9%-
Equity YoY growth-20%21%-8K%236%-38%18%217%16%-34%28%
FCF YoY growth---14K%-69%312%-78%316%123%27%-